SCHEMBL7980052

SCHEMBL7980052

CCOC(=O)CC(CN)CC(C)C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA2D1 P54289 2/20 0.58
CACNB3 P54284 1/20 0.58
CACNA1C Q13936 1/20 0.58
PGR P06401 1/20 0.58
ADRA1A P35348 1/20 0.58
HTR2B P41595 1/20 0.58
CACNA2D2 Q9NY47 1/20 0.58
CYP1A2 P05177 1/20 0.41
MGAM O43451 1/20 0.40
GAA P10253 1/20 0.40
SI P14410 1/20 0.40
MGAM2 Q2M2H8 1/20 0.40
ALDH1A1 P00352 6/20 0.38
TRPA1 O75762 1/20 0.38
ALOX15 P16050 3/20 0.36
CYP3A4 P08684 2/20 0.36
TSHR P16473 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
CHRM1 P11229 1/20 0.35
ADORA1 P30542 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15698640 1.00 CACNA2D1 (0.58) CACNA2D1CACNB3CACNA1CPGRADRA1A
Hydrochloric Acid SCHEMBL30695404 0.98 CACNA2D1 (0.56) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL234997 0.88 MGAM (0.46) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL8320348 0.86 CACNA2D1 (0.42) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL27539220 0.85 MGAM (0.43) CACNA2D1CACNB3CACNA1CPGRADRA1A
Hydrochloric Acid SCHEMBL30512140 0.84 CACNA2D1 (0.53) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL21589071 0.84 CACNA2D1 (0.39) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL27857355 0.84 CACNA2D1 (0.39) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL4329152 0.84 CACNA2D1 (0.39) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL8057583 0.83 MGAM (0.41) CACNA2D1CACNB3CACNA1CPGRADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105367434-A Method for synthesizing pregabalin from isobutyraldehyde TAICANG YUNTONG BIOCHEMICAL ENG CO LTD 2016-03-02 CN claimed
CN-105348126-A Method for synthesizing Pregabalin by taking chloroacetonitrile and isobutylaldehyde as raw materials TAICANG YUNTONG BIOCHEMICAL ENGINEERING CO LTD 2016-02-24 CN claimed
CN-105367434-A Method for synthesizing pregabalin from isobutyraldehyde TAICANG YUNTONG BIOCHEMICAL ENG CO LTD 2016-03-02 CN disclosed
CN-105348126-A Method for synthesizing Pregabalin by taking chloroacetonitrile and isobutylaldehyde as raw materials TAICANG YUNTONG BIOCHEMICAL ENGINEERING CO LTD 2016-02-24 CN disclosed
US-8546112-B2 Process for the stereoselective enzymatic hydrolysis of 5-methyl-3-nitromethyl-hexanoic acid ester SANDOZ AG (CH) 2013-10-01 US disclosed
EP-2294207-B1 Process for the stereoselective enzymatic hydrolysis of 5-methyl-3-nitromethyl-hexanoic acid ester SANDOZ AG (CH) 2012-09-26 EP disclosed
US-20110165636-A1 PROCESS FOR THE STEREOSELECTIVE ENZYMATIC HYDROLYSIS OF 5-METHYL-3-NITROMETHYL-HEXANOIC ACID ESTER SANDOZ AG (CH) 2011-07-07 US disclosed
WO-2009141362-A2 PROCESS FOR THE STEREOSELECTIVE ENZYMATIC HYDROLYSIS OF 5-METHYL-3-NITROMETHYL-HEXANOIC ACID ESTER SANDOZ AG (CH) 2009-11-26 WO disclosed
WO-2009044409-A2 NOVEL RESOLUTION PROCESS FOR PREGABALIN NATCO PHARMA LIMITED (IN) 2009-04-09 WO disclosed
US-20080045747-A1 Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-pregabalin KANSAL VINOD K 2008-02-21 US disclosed
US-20080045747-A1 Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-pregabalin KANSAL VINOD K 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045747-A1 Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-pregabalin GABRE, GABRA5, GABRA6 CACNA2D1 219/4885CACNB3 190/4885CACNA1C 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.